Showing results (111-120 of 154) with videos related to

Sort By:
Pageof 16
Leukemia & Lymphoma|September 1, 2021
Clinical characteristics and prognostic factors of 70 patients with Sézary syndrome: a single-institutional experience at Moffitt cancer centerYumeng Zhang, Lucia Seminario-Vidal, Christa Varnadoe, et al.
Molecular Immunology|August 27, 2014
Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and functionEva Sahakian, John J Powers, Jie Chen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 10, 2014
A novel role for histone deacetylase 6 in the regulation of the tolerogenic STAT3/IL-10 pathway in APCsFengdong Cheng, Maritza Lienlaf, Hong-Wei Wang, et al.
Blood Advances|July 8, 2020
The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cellsKamira Maharaj, John J Powers, Alex Achille, et al.
Hematology (Amsterdam, Netherlands)|October 7, 2025
Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phaseEhab Atallah, Michael S Broder, Onyee Chan, et al.
JAMA Network Open|December 18, 2023
Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid LeukemiaAaron N Winn, Ehab Atallah, Jorge Cortes, et al.
Haematologica|December 9, 2016
Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemiaJorge Cortes, Moshe Talpaz, Hedy P Smith, et al.
Transplantation and Cellular Therapy|March 30, 2021
Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell LymphomaAbu-Sayeef Mirza, Ambuj Kumar, Hamza Hashmi, et al.
Blood Advances|February 12, 2025
Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent modelWael Gamal, Nienke B Goedhart, Helga Simon-Molas, et al.
Leukemia|January 29, 2024
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trialsElias Jabbour, Jane Apperley, Jorge Cortes, et al.
Pageof 16